TY - JOUR
T1 - New approaches for temozolomide therapy
T2 - Use in newly diagnosed glioma
AU - Stupp, Roger
AU - Newlands, Edward
PY - 2001
Y1 - 2001
N2 - Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma. Treatment with temozolomide is now being explored in patients with newly diagnosed malignant glioma in several ongoing clinical trials, and alternative treatment schedules are being evaluated. A schedule of continuous daily treatment with temozolomide for 6 or 7 weeks has been developed and determined to be safe, effective, and well tolerated. When temozolomide was continuously given along with a standard course of radiation therapy for 6 or 7 weeks, followed by adjuvant treatment with temozolomide, promising preliminary results were seen in patients with malignant gliomas.
AB - Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma. Treatment with temozolomide is now being explored in patients with newly diagnosed malignant glioma in several ongoing clinical trials, and alternative treatment schedules are being evaluated. A schedule of continuous daily treatment with temozolomide for 6 or 7 weeks has been developed and determined to be safe, effective, and well tolerated. When temozolomide was continuously given along with a standard course of radiation therapy for 6 or 7 weeks, followed by adjuvant treatment with temozolomide, promising preliminary results were seen in patients with malignant gliomas.
UR - http://www.scopus.com/inward/record.url?scp=0034823436&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034823436&partnerID=8YFLogxK
U2 - 10.1053/sonc.2001.26650
DO - 10.1053/sonc.2001.26650
M3 - Review article
C2 - 11550135
AN - SCOPUS:0034823436
VL - 28
SP - 19
EP - 23
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 4 SUPPL. 13
ER -